<DOC>
	<DOCNO>NCT00109811</DOCNO>
	<brief_summary>This phase II trial study well vaccine therapy work treat patient recurrent prostate cancer . Vaccines make peptide may help body build effective immune response kill tumor cell</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine T-lymphocyte immune response patient recurrent adenocarcinoma prostate treat prostate-specific antigen ( PSA ) peptide vaccine ( PSA-3A ; PSA : 154-163 [ 155L ] ) emulsify Montanide ISA-51 . SECONDARY OBJECTIVES : I . Determine toxicity vaccine patient . II . Determine effect vaccine serum PSA level patient . OUTLINE : This pilot study . Patients receive prostate-specific antigen ( PSA ) peptide vaccine ( PSA-3A ; PSA : 154-163 [ 155L ] ) emulsify Montanide ISA-51 subcutaneously week 0 , 2 , 4 , 6 , 10 , 14 , 18 absence disease progression* unacceptable toxicity . NOTE : *A rise PSA alone consider disease progression . After completion study treatment , patient follow 1 4 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Must undergone radical prostatectomy ≥ 3 month ago Prostatespecific antigen ( PSA ) level ≥ 0.6 ng/mL rise ( radical prostatectomy ) ≥ 2 measurement separate ≥ 3 month HLAA2positive peripheral blood mononuclear cell flow cytometry No clinical evidence local recurrence No palpable induration mass prostatic fossa No metastatic prostate cancer No osseous metastasis bone scan Performance status ECOG 01 Performance status Karnofsky 70100 % More 1 year WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 AST ALT ≤ 2.5 time upper limit normal Bilirubin normal Hepatitis B C negative Creatinine normal Creatinine clearance ≥ 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No history allergic reaction attribute compound similar chemical biologic composition study PSA peptide vaccine Montanide ISA51 No history systemic autoimmune disease autoimmune disease require antiinflammatory immunosuppressive therapy Patients history autoimmune thyroiditis eligible provide patient require thyroid hormone replacement therapy AND disease stable ≥ 1 year No know HIV positivity No ongoing active infection No primary secondary immune deficiency No psychiatric illness social situation would preclude study compliance No history uncontrolled illness No prior chemotherapy No prior hormonal therapy No concurrent systemic ocular steroid therapy , except follow : Inhaled steroid asthma Limited topical steroid Replacement dose cortisone More 4 week since prior radiotherapy No prior radiotherapy prostate Prior radiotherapy pelvis radical prostatectomy allow See Disease Characteristics No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>